Anwaar Saeed, MD, University of Kansas Medical Center, Kansas City, MO, discusses the Phase I/II RiME trial (NCT03995017), investigating the use of the triplet combination of nivolumab, rucaparib and ramucirumab in patients with microsatellite-stable advanced gastric or esophageal adenocarcinoma. The hope is to use this treatment in the second-line or maintenance setting. Previous studies in other cancers have supported the idea of combining a PARP inhibitor with immunotherapy. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

свернуть